🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 54 of 757 · Phase 3 first, then by program name

  1. Experimental vaccine

    SINOVAC BIOTECH LTD

    Poliomyelitis

    phase 3 mab completed

    1 trial

  2. Expressive Writing

    United Therapeutics Europe Ltd

    Posttraumatic Stress Disorder

    phase 3 other completed

    1 trial

  3. Extended Release Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 3 small molecule completed

    1 trial

  4. Extended Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  5. Extended treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 small molecule completed

    1 trial

  6. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda Pharmaceuticals International AG

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  7. Extended-release Guanfacine Hydrochloride

    Takeda Pharmaceuticals International AG

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  8. Extensively Hydrolyzed formula

    United Therapeutics Europe Ltd

    Cow Milk Allergy

    phase 3 other completed

    1 trial

  9. Eylea (Aflibercept, BAY86-5321)

    Regeneron UK Limited

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    2 trials

  10. Eylea 40 mg/mL solution for injection in a vial

    Pharma Mar S.A.

    Retinopathy of prematurity (ROP)

    phase 3 small molecule active

    1 trial

  11. FAMPRIDINE, Placebo 515

    Pari Pharma GmbH

    Spinocerebellar ataxia

    phase 3 small molecule active

    1 trial

  12. FAT EMULSIONS , Triheptanoin

    Pharma Mar S.A.

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 3 small molecule active

    1 trial

  13. FEIBA

    Takeda Pharmaceuticals International AG

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  14. FET

    Disc Medicine

    ACTH-dependent hypercortisolism

    phase 3 small molecule active

    1 trial

  15. FF/UMEC/VI

    Grace Therapeutics

    Asthma

    phase 3 small molecule active

    1 trial

  16. FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  17. FILGRASTIM, CYCLOPHOSPHAMIDE, DOXORUBICIN, DEXRAZOXANE HYDROCHLORIDE

    Cancer Prevention Pharma (Ireland) Limited

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

  18. FLECAINIDE

    Pari Pharma GmbH

    Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardia

    phase 3 small molecule active

    1 trial

  19. FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  20. FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial

  21. FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA

    Fondazione Telethon ETS

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  22. FLUOROURACIL , CAPECITABINE , Folikabi 10 mg/ml oplossing voor injectie/infusie, OXALIPLATIN

    Disc Medicine

    Rectal cancer

    phase 3 small molecule active

    1 trial

  23. FLUOROURACIL , OXALIPLATIN , GEMCITABINE , FOLIC ACID

    Pari Pharma GmbH

    Pancreatic adenocarcinoma (PAC)

    phase 3 small molecule active

    1 trial

  24. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources